Ferroptosis

Cat. No.

A15865

CAS No.

1219810-16-8

RSL3

Synonyms: 1S,3R-RSL3

RSL3 is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS.

Cat. No.

A18381

CAS No.

537-98-4

(E)-Ferulic acid

(E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls. (E)-Ferulic acid shows a potent ability to remove reactive oxygen species (ROS) and inhibits lipid peroxidation. (E)-Ferulic acid exerts both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.

Cat. No.

A19721

CAS No.

1083162-61-1

FIN56

FIN56 is a specific inducer of ferroptosis.

Cat. No.

A20358

CAS No.

1948-33-0

TBHQ

Synonyms: tert-Butylhydroquinone

TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2.

Cat. No.

A20781

CAS No.

16009-13-5

Hemin

Synonyms: Hemin chloride

Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.

Cat. No.

A24555

CAS No.

19121-58-5

Solasonine

Solasonine is a naturally occurring steroidal glycoalkaloid isolated from *Solanum melongena* (eggplant), known for its anti-infective, anticancer, and neurogenesis-promoting properties. It acts as a ferroptosis inducer by disrupting the glutathione redox system through inhibition of glutathione peroxidase 4 (GPX4). By promoting ferroptotic cell death in hepatocellular carcinoma (HCC) cells, Solasonine serves as a valuable compound for investigating ferroptosis mechanisms and developing novel anticancer strategies.

Cat. No.

A25391

CAS No.

1884647-72-6

Ironomycin

Ironomycin is an apoptosis and ferroptosis inducer that targets critical pathways in cancer biology. This compound demonstrates selective inhibitory effects against mantle cell lymphoma (MCL) cells by inducing cell cycle arrest and promoting apoptosis and ferroptosis. Ironomycin causes double-strand DNA breaks and activates the unfolded protein response (UPR), particularly through the IRE1α signaling pathway. The combination of Ironomycin with Ibrutinib yields a synergistic effect, making it a valuable reagent for studying MCL and exploring therapeutic strategies in cancer research.

Cat. No.

A26744

CAS No.

1185-57-5

Ammonium iron(III) citrate

Synonyms: Ammonium ferric citrate; FAC

Ammonium iron(III) citrate serves as a ferroptosis activator through the induction of intracellular iron overload. By increasing cellular iron levels, it promotes oxidative stress and contributes to ferroptotic cell death. This compound is valuable for research involving cellular iron metabolism, oxidative stress studies, and investigations into ferroptosis-related pathways. Additionally, it may enhance protein production, making it relevant for applications in biochemical assays and cellular biology research.

Cat. No.

A26845

CAS No.

2933939-15-0

Ferroptosis inducer-6

Ferroptosis Inducer-6 is a potent inducer of ferroptosis, primarily functioning through the generation of reactive oxygen species (ROS) and the induction of oxidative stress and mitochondrial damage. This compound exhibits anti-tumor activity and serves as a valuable tool for research in type I and II photodynamic therapy. Its ability to trigger ferroptotic cell death makes it significant for studies focused on cancer treatment and exploring the mechanisms of cell death pathways.

Cat. No.

A26853

CAS No.

444914-19-6

Lepadin E

Lepadin E is a potent ferroptosis inducer that activates cell death through the classical p53-SLC7A11-GPX4 pathway. By promoting p53 expression and downregulating SLC7A11 and GPX4, Lepadin E enhances reactive oxygen species (ROS) and lipid peroxide production while increasing ACSL4 expression. This mechanism underlies its significant antitumor efficacy, making Lepadin E a valuable tool for studying ferroptosis in cancer research.

Cat. No.

A26856

CAS No.

412328-25-7

Lepadin H

Lepadin H is a potent ferroptosis and apoptosis inducer, demonstrating significant in vitro cytotoxicity and in vivo antitumor efficacy against cancer cells. This compound functions by decreasing the levels of GPX4 and SLC7A11, while enhancing p53 and ACSL4 expression. Lepadin H promotes the generation of lipid hydroperoxides and increases reactive oxygen species (ROS), leading to a reduction in cellular glutathione (GSH) levels and lipid peroxidation. Additionally, it causes G2/M phase cell cycle arrest and inhibits the clonogenic growth and migration of melanoma cells, making it a valuable tool for cancer research.

Cat. No.

A26857

CAS No.

1008482-71-0

AX-53802

AX-53802 is a potent ferroptosis inducer that targets glutathione peroxidase 4 (GPX4) with an IC50 value of 0.34 µM. This compound covalently binds to GPX4, facilitating membrane translocation and subsequent triggering of ferroptotic cell death. In combination with FAK/Src inhibitors, AX-53802 enhances the induction of cell death, making it a valuable tool for cancer research and studies involving ferroptosis mechanisms.

Cat. No.

A26860

CAS No.

2723569-00-2

Ferroptosis inducer-7

Ferroptosis inducer-7 selectively induces ferroptosis via the inositol 1,4,5-trisphosphate receptor (IP3R) and calcium release-activated calcium channel protein (ORAI). This compound demonstrates significant biological activity in alleviating symptoms of anemia, suppressing activation of bone marrow cytotoxic T lymphocytes (CTLs), and enhancing hematopoietic function in cases of immune-mediated bone marrow failure. Ferroptosis inducer-7 is valuable for research applications focused on aplastic anemia and related hematological conditions.

Cat. No.

A26870

CAS No.

2241283-11-2

Anticancer agent 147

Anticancer agent 147 is a ferroptosis inducer that promotes intracellular accumulation of Fe2+, reactive oxygen species (ROS), and malondialdehyde (MDA). This compound enhances endoplasmic reticulum (ER) stress and upregulates the expression of activating transcription factor ATF3. Anticancer agent 147 exhibits significant anti-liver cancer effects in both in vitro and in vivo models, making it a valuable tool for research in cancer therapy and cell death mechanisms.

Cat. No.

A26877

CAS No.

2942242-60-4

GIC-20

GIC-20 is a dual inducer of apoptosis and ferroptosis, acting on key cellular pathways involved in programmed cell death. This compound demonstrates significant antitumor efficacy, particularly against fibrosarcoma. GIC-20 is valuable for research applications aimed at exploring mechanisms of cell death and potential therapeutic strategies in cancer biology.

Cat. No.

A26882

CAS No.

39916-28-4

Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III)

Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) acts as a ferroptosis inducer by generating lipid-based reactive oxygen species (ROS). This compound is instrumental for research exploring the mechanisms of ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. It is valuable for studies investigating cancer biology, neurodegenerative diseases, and other conditions where ferroptosis plays a critical role.

Cat. No.

A26887

CAS No.

2505218-38-0

Ferroptocide

Ferroptocide is a potent inducer of ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. It effectively induces oxidative stress, resulting in G2/M cell cycle arrest and apoptosis in LNCaP cells, and significantly reduces cell viability in both LNCaP and TRAMP-C1 prostate cancer cell lines. Ferroptocide serves as a valuable tool for investigating mitochondrial autophagy and evaluating its potential to trigger immunogenic cell death (ICD) in prostate cancer research.

Cat. No.

A26895

CAS No.

55945-74-9

Chaetoglobosin E

Chaetoglobosin E is a potent ferroptosis inducer that targets and downregulates GPX4 expression in human tumor cell lines. It exhibits significant cytotoxic effects, with IC50 values of 9.14 μM against MDA-MB231 cells and 7.47 μM against A549 cells. The compound elevates intracellular Fe2+ levels and increases the lipid peroxidation marker malondialdehyde (MDA), resulting in mitochondrial alterations and the induction of ferroptosis. Chaetoglobosin E serves as a valuable tool for cancer research and the study of ferroptosis mechanisms.

Cat. No.

A26898

CAS No.

2375357-99-4

Fluorescein-diisobutyrate-6-amide

Fluorescein-diisobutyrate-6-amide is a potent ferroptosis inducer targeting the cell death pathway associated with iron metabolism. This compound primarily promotes oxidative stress, leading to lipid peroxidation and subsequent cell apoptosis. Fluorescein-diisobutyrate-6-amide is valuable for research applications in cancer biology, particularly in understanding ferroptosis mechanisms and exploring novel therapeutic strategies against various malignancies.

Cat. No.

A26900

CAS No.

273199-42-1

Talaroconvolutin A

Talaroconvolutin A is a potent ferroptosis inducer that primarily acts by elevating reactive oxygen species (ROS) levels while bypassing the GPX4 pathway. This compound downregulates the expression of solute carrier family 7 member 11 (SLC7A11) and enhances arachidonic acid lipoxygenase 3 (ALOXE3) levels. Talaroconvolutin A demonstrates significant cytotoxicity in colorectal cancer cells (HCT116) and bladder cancer cells (SW480), with IC50 values of 1.22 μM and 1.4 μM, respectively. This reagent is valuable for researching ferroptosis mechanisms and therapeutic strategies in colorectal and bladder cancers.

Cat. No.

A26906

CAS No.

2375357-97-2

(1R,3R)-Ferroptosis inducer-1

(1R,3R)-Ferroptosis inducer-1 is a selective ferroptosis inducer that demonstrates significant antitumor activity. This compound promotes ferroptotic cell death, a form of regulated necrosis characterized by lipid peroxidation, making it valuable for research in cancer biology. It has potential applications in the study of therapeutic strategies targeting ferroptosis in various cancer types.

Cat. No.

A26916

CAS No.

3031762-97-4

NA-Ir

NA-Ir is a potent ferroptosis inducer that targets mitochondrial DNA (mtDNA) and activates the cGAS-STING signaling pathway, promoting ferritinophagy. It generates reactive oxygen species (ROS) through photodynamic therapy (PDT) while depleting glutathione (GSH) and downregulating glutathione peroxidase 4 (GPX4), leading to lipid peroxidation and the initiation of ferroptosis. NA-Ir demonstrates increased anticancer efficacy when exposed to light, selectively impairing cancer cells characterized by elevated levels of hydrogen sulfide (H2S).

Cat. No.

A26923

CAS No.

3097194-74-3

Ferroptosis inducer-8

Ferroptosis inducer-8 is a potent ferroptosis inducer that selectively targets other cell death pathways. It functions by modulating the expression of ACSL4, GPX4, and FTH1, thereby disrupting iron homeostasis and impairing the GSH/GPX4 antioxidant defense system. This mechanism facilitates lipid peroxidation and promotes reactive oxygen species (ROS) production. Ferroptosis inducer-8 has demonstrated efficacy in inhibiting tumor growth, making it a valuable tool for research in triple-negative breast cancer (TNBC) and other malignancies.

Cat. No.

A26929

CAS No.

3065877-52-0

BG11

BG11 is a potent ferroptosis inducer that promotes the accumulation of Fe2+ ions and intracellular lipid peroxides, leading to ferroptotic cell death. It modulates the expression of apoptotic regulators such as Bax and Bcl-2, facilitating apoptosis in MDA-MB-231 breast cancer cells. Furthermore, BG11 causes G0/G1 and S phase cell cycle arrest, significantly inhibiting the proliferation, migration, and invasion of triple-negative breast cancer (TNBC) cells, with IC50 values of 0.49 μM for MDA-MB-231 and 0.52 μM for BT549. In preclinical mouse models, BG11 demonstrates notable antitumor efficacy.

Cat. No.

A26933

CAS No.

3060507-88-9

anti-TNBC agent-13

Anti-TNBC agent-13 is a ferroptosis inducer designed to target and inhibit GPX4 activity. By promoting the accumulation of lipid peroxides, it triggers cell death specifically in triple-negative breast cancer (TNBC) cells. This compound serves as a valuable research tool for studying ferroptosis and its therapeutic potential in TNBC.